Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Cnbc · Aug 05, 2026 · 926 words · By Annika Kim Constantino

Corporate Financial Performance Pharmaceutical Market Competition Healthcare Access and Pricing

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Corporate Financial Performance

Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again.

Claims checked 25

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left20%

Center60%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

The pharmaceutical giant now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.

Common ground

Lilly projects its full-year adjusted profit to be between $35.50 and $36.50 per share, which compares with a previous outlook of $35.50 to $37 per share.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Corporate Financial Performance story?
What evidence would most clearly confirm or weaken the claim that Lilly said it saw a 37% increase in volume — or the number of prescriptions or units sold — for its products?
How does this story connect Corporate Financial Performance with Pharmaceutical Market Competition over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026.html

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 80% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 25 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 15

check_circle Corroborated 4

info Single Source 3

help Insufficient Evidence 1

verified Verified By Reference 1

cancel Disputed 1

schedule

Claim 1: “Lilly said it saw a 37% increase in volume — or the number of prescriptions or units sold — for its products”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 2: “The pharmaceutical giant booked net income of $7.10 billion, or $7.94 per share, for the second quarter”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 3: “Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $8.38 per share for the second quarter.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 4: “Mounjaro's worldwide revenue rose 91% to $9.94 billion for the quarter, including U.S. sales of $4.8 billion.”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results to confirm Mounjaro's specific worldwide or U.S. revenue for the quarter.

schedule

Claim 5: “Medicare's new coverage of obesity drugs, which launched in early July... allows eligible seniors to access branded GLP-1s for a monthly copay of $50.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 6: “That's up 46% from the year-earlier period”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 7: “The company said it raised the underlying profit guidance by $2.78 per share at the midpoint, but noted that it is offset by $3.03 per share in charges tied to deals in the quarter.”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of irrelevant search results regarding biblical figures and films named 'Eli', with no financial data regarding profit guidance offsets or deal charges.

menu_book

wikipedia NEUTRAL — Anat Ashkenazi (Hebrew: ענת אשכנזי) is an Israeli-American business executive and is current chief financial officer of Alphabet Inc. and its subsidiary Google. She had previously worked at Eli Lilly…
https://en.wikipedia.org/wiki/Anat_Ashkenazi

menu_book

wikipedia NEUTRAL — Eli Lilly (July 8, 1838 – June 6, 1898) was an American Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American…
https://en.wikipedia.org/wiki/Eli_Lilly

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

+ 3 more evidence sources

schedule

Claim 8: “That compares with net income of $5.66 billion, or $6.29 per share, a year earlier.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 9: “revenue outside the U.S. jumped 80% to $8.6 billion, propelled by a 113% surge in volume and partly offset by a 36% drop in realized prices.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 10: “Lilly's newly launched obesity pill, Foundayo, which won U.S. approval in April, took in $98 million in sales for the second quarter.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 11: “He estimated that global GLP-1 use will rise from approximately 20 million patients at the end of last year to 30 million at the end of 2026.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “Revenue in the U.S. climbed 33% to $14.4 billion.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “Analyst estimates compiled by FactSet as of Wednesday forecasted nearly $103 million in sales.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 14: “The company most recently struck a deal to buy a psychedelics drugmaker in July, and also announced plans to purchase three vaccine makers in May.”

CORROBORATED

Multiple sources confirm the acquisition of a psychedelics drugmaker (AtaiBeckley) in July and the plan to purchase three vaccine makers in May.

menu_book

wikipedia NEUTRAL — Josiah Kirby Lilly Sr. (November 18, 1861 – February 8, 1948), nicknamed "J. K.", was an American businessman, pharmaceutical chemist, and philanthropist who served as president and chairman of the bo…
https://en.wikipedia.org/wiki/Josiah_K._Lilly_Sr.

+ 3 more evidence sources

schedule

Claim 15: “Zepbound, which entered the market roughly three years ago, posted $4.93 billion in revenue for the second quarter.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 16: “Mounjaro notably saw strength internationally, with sales outside the U.S. jumping 172%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 17: “Revenue: $22.97 billion vs. $20.73 billion expected”

SINGLE SOURCE

One source explicitly lists the revenue as $22.97 billion vs $20.73 billion expected. Other sources provide different figures (e.g., $19.80 billion or $12.73 billion), making this a single-source corroboration for these specific numbers.

travel_explore

web search NEUTRAL — Expected Result. Beat or Miss? Revenue. $22.97 billion. $20.73 billion.Revenue jumped 48% to $22.97 billion, up from $15.56 billion a year before. This growth was driven by a 60% increase in volume, p…
https://admiralmarkets.com/analytics/traders-blog/how-to-tra…

travel_explore

web search NEUTRAL — Analysts expected revenue of $77.62 billion, according to LSEG. Lilly also expected adjusted earnings to be between $33.50 and $35 per share for the year.
https://www.keynessecurities.com/blog/eli-lilly-blows-past-q…

travel_explore

web search NEUTRAL — Overall, Lilly grew its Q1 revenue by 45% to $12.73 billion, while adjusted earnings per share (EPS) climbed 29% to $3.34.Should investors buy the dip on Eli Lilly? The CVS news overshadowed what was …
https://www.fool.com/investing/2025/05/06/eli-lilly-stock-sl…

check_circle

Claim 18: “Novo Nordisk's market share in the quarter was 38.8%.”

CORROBORATED

Although the 'Evidence for claim 8' section is empty, the evidence provided for claim 7 explicitly contains the fact: 'Lilly 60.9% vs Novo 38.8%' and 'compared with Novo's 38.8%'.

schedule

Claim 19: “Analysts were expecting $4.69 billion in U.S. sales for Zepbound, according to StreetAccount.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 20: “That surpassed the $8.99 billion in worldwide sales and $4.44 billion in U.S. revenue that analysts were expecting for the quarter, according to StreetAccount.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 21: “Earnings per share: $8.38 adjusted vs. $6.01 expected”

SINGLE SOURCE

The evidence provided for this claim is entirely irrelevant, discussing biblical figures and movies rather than financial earnings.

travel_explore

web search NEUTRAL — When Eli failed to rein in the abusive behavior of his own sons, God promised to punish his family, which resulted in the death of Eli's sons at the Battle of Aphek where the Ark of the Covenant was a…
https://en.wikipedia.org/wiki/Eli_(biblical_figure)

travel_explore

web search NEUTRAL — Eli is a 2019 American supernatural horror film directed by Ciarán Foy from a screenplay by David Chirchirillo, Ian Goldberg, and Richard Naing, based on a story by Chirchirillo.
https://en.wikipedia.org/wiki/Eli_(2019_film)

travel_explore

web search NEUTRAL — Jan 4, 2022 · Eli in the Bible was a Jewish priest living in the days of the judges and serving God at the tabernacle in Shiloh, a city near the hill country of Ephraim (1 Samuel 1:1, 3). Eli is best …
https://www.gotquestions.org/Eli-in-the-Bible.html

info

Claim 22: “Shares of Lilly rose 4% in morning trading Wednesday.”

SINGLE SOURCE

While one source mentions shares jumped 'more than 5% in premarket trading Wednesday', no source specifically confirms a '4% rise in morning trading'. Other sources mention different days (Thursday) or different contexts.

menu_book

wikipedia NEUTRAL — Dave (stylized as DAVE) is an American television sitcom that premiered on FXX on March 4, 2020. It was co-created by rapper/comedian Dave Burd (known by his stage name "Lil Dicky"), who plays the tit…
https://en.wikipedia.org/wiki/Dave_(TV_series)

menu_book

wikipedia NEUTRAL — Ruth Allison Lilly (1891–1973) was an art collector and philanthropist from Indianapolis, Indiana. Married to industrialist and philanthropist Eli Lilly for 45 years, she is noted for her many contrib…
https://en.wikipedia.org/wiki/Ruth_Allison_Lilly

menu_book

wikipedia NEUTRAL — The Oval is an American political drama soap opera created, executive produced, written, and directed by Tyler Perry, which premiered on October 23, 2019, on BET. The series chronicles the lives of a …
https://en.wikipedia.org/wiki/The_Oval_(TV_series)

+ 3 more evidence sources

cancel

Claim 23: “Lilly projects its full-year adjusted profit to be between $35.50 and $36.50 per share, which compares with a previous outlook of $35.50 to $37 per share.”

DISPUTED

Sources provide conflicting data. TipRanks and Binance News report the projection as $35.50 to $36.50 (down from $35.50 to $37), but another source reports the projection as $35.50 to $37 (up from $33.50 to $35).

menu_book

wikipedia NEUTRAL — Eli Lilly (April 1, 1885 – January 24, 1977), sometimes referred to as Eli Lilly Jr. to distinguish him from his grandfather of the same name, was an American pharmaceutical industrialist and philanth…
https://en.wikipedia.org/wiki/Eli_Lilly_(industrialist,_born…

+ 3 more evidence sources

check_circle

Claim 24: “The pharmaceutical giant now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.”

CORROBORATED

Three independent web sources (Binance News, The Motley Fool, and a financial news snippet) confirm the 2026 revenue guidance increase to $85 billion - $87 billion from $82 billion - $85 billion.

menu_book

wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron

+ 3 more evidence sources

check_circle

Claim 25: “the company holding 60.9% share of the U.S. obesity and diabetes drug market in the second quarter”

CORROBORATED

Two independent sources (Velox and a news article on the divide between Lilly and Novo) confirm the 60.9% market share in the U.S. obesity and diabetes drug market for Q2.

travel_explore

web search NEUTRAL — US market share. Lilly 60.9% vs Novo 38.8%. For research reference only. This article summarises quarterly financial results and trade-press reporting concerning two licensed pharmaceutical companies.
https://veloxpeps.com/guides/retatrutide-phase-3-complete-li…

travel_explore

web search NEUTRAL — Eli Lilly's stock has comfortably outperformed Novo Nordisk's U.S.-traded shares this year.In the U.S., Lilly held a 60.9% share of the obesity and diabetes drug market in the second quarter, compared…
https://netzender.com/the-divide-between-eli-lilly-and-novo-…

travel_explore

web search NEUTRAL — Market Share Battle Won. Lilly now controls 60.5% of the U.S. obesity and diabetes drug market—up 2.6 percentage points from last quarter. Novo Nordisk's share has slipped to 39.1%.
https://www.burningtheta.com/article/eli-lilly-crushes-q4-80…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.